Anavex Life Sciences Corp.
0HFR.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$138.08M
Close$
$1.20
20.4% downside
Current Fair Value
20.4% downsideOvervalued by 20.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $138.08 Million |
|---|---|
| Enterprise Value | $19.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.54 |
| Beta | 1.14 |
| Outstanding Shares | 92,696,842 |
Return
| Return on Equity | -21.38% |
|---|---|
| Return on Assets | -20.01% |
| Return on Invested Capital | -23.37% |
Valuation & Multiples
| P/E Ratio | -5.7 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.75 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 24, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Anavex Life Sciences Corporation
34 employees
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...